3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Leukemia, Myeloid, Acute
11
Multiple Myeloma
7
Sarcoma
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Neoplasm Metastasis
3
Melanoma
3
Lymphoma, Non-Hodgkin
3
Lymphoma, Large B-Cell, Diffuse
3
Recurrence
2
Ovarian Neoplasms
2
Neurofibrosarcoma
2
Myelodysplastic Syndromes
2
Lymphoma, T-Cell, Peripheral
2
Lymphoma
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Leukemia, Biphenotypic, Acute
2
Glioblastoma
2
Congenital Abnormalities
2
Colorectal Neoplasms
2
Central Nervous System Neoplasms
2
Adenocarcinoma
2
Waldenstrom Macroglobulinemia
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Solid Tumors
1
Sarcoma, Ewing
1
Sarcoma, Endometrial Stromal
1
Sarcoma, Alveolar Soft Part
1
Rhabdoid Tumor
1
Interventions
Cyclophosphamide
38
fludarabine
30
Rituximab
26
obinutuzumab
10
Bendamustine Hydrochloride
10
fludarabine phosphate
9
pembrolizumab
8
Specimen Handling
7
Etoposide
7
venetoclax
6
Vincristine
6
Prednisone
6
Magnetic Resonance Spectroscopy
6
Leukapheresis
6
Lenalidomide
6
ibrutinib
5
Inotuzumab Ozogamicin
5
Immunotherapy, Adoptive
5
Doxorubicin
5
Biopsy
5
ublituximab
4
tazemetostat
4
glofitamab
4
Interleukin-2
4
Dexamethasone
4
Cytarabine
4
pomalidomide
3
polatuzumab vedotin
3
Radiation
3
Nivolumab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Lymphoma, B-Cell
×
selinexor
×
Clear all
NCT02741388
2021-12-07
SELINDA
The Lymphoma Academic Research Organisation
Phase 1
Completed
39 enrolled